NCT04552743View on ClinicalTrials.gov

MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

July 22, 2021

Study Completion Date

June 30, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

MGTA-145

A chemokine receptor type 2 (CXCR2) agonist protein, administered via intravenous (IV) infusion over 3 to 10 minutes.

DRUG

Plerixafor

An azamacrocycle CXCR4 chemokine receptor antagonist, administered at 0.24 mg/kg subcutaneously, reduced to 0.16 mg/kg in patients with renal dysfunction (per package insert).

Trial Locations (1)

94304

Stanford University, Stanford

All Listed Sponsors
lead

Surbhi Sidana, MD

OTHER

NCT04552743 - MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma | Biotech Hunter | Biotech Hunter